Preferential activation of SMAD1/5/8 on the fibrosa endothelium in calcified human aortic valves - association with low BMP antagonists and SMAD6

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Ankeny, Randall F ^a   Thourani, Vinod H ^b   Weiss, Daiana ^b   Vega, J David ^b   Taylor, W Robert ^a,b   Nerem, Robert M ^a   Jo, Hanjoong ^a,b,c  

^a GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Ewha Womans University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN 6; PROTEIN INHIBITOR; SMAD1 PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD5 PROTEIN; SMAD6 PROTEIN; SMAD8 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; SMAD PROTEIN;

AGED; AORTA VALVE DISEASE; AORTA WALL; ARTICLE; CALCIFICATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEART VENTRICLE WALL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM; AORTA VALVE; CALCINOSIS; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; MIDDLE AGED;

AGED; AGED, 80 AND OVER; AORTIC VALVE; BONE MORPHOGENETIC PROTEINS; CALCINOSIS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; MIDDLE AGED; SMAD PROTEINS;

EID: 79958818345     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020969     Document Type: Article

References (41)

1. Hsu SY, Hsieh IC, Chang SH, Wen MS, Hung KC, (2005) Aortic valve sclerosis is an echocardiographic indicator of significant coronary disease in patients undergoing diagnostic coronary angiography. Int J Clin Pract 59: 72-77.
2. Mohler ER, Sheridan MJ, Nichols R, Harvey WP, Waller BF, (1991) Development and progression of aortic valve stenosis: atherosclerosis risk factors-a causal relationship? A clinical morphologic study. Clin Cardiol 14: 995-999.
3. Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS, et al. (1999) Association of Aortic-Valve Sclerosis with Cardiovascular Mortality and Morbidity in the Elderly. N Engl J Med 341: 142-147.
4. Thourani VH, Myung R, Kilgo P, Thompson K, Puskas JD, et al. (2008) Long-Term Outcomes After Isolated Aortic Valve Replacement in Octogenarians: A Modern Perspective. The Annals of Thoracic Surgery 86: 1458-1465.
5. Mohler ER 3rd, (2000) Are atherosclerotic processes involved in aortic-valve calcification? Lancet 356: 524-525.
6. Mohler ER, (2004) Mechanisms of Aortic Valve Calcifcation. Am J Cardiol 94: 1396-1402.
7. Parolari A, Loardi C, Mussoni L, Cavallotti L, Camera M, et al. (2009) Nonrheumatic calcific aortic stenosis: an overview from basic science to pharmacological prevention. European Journal of Cardio-Thoracic Surgery 35: 493-504.
8. Jian B, Jones PL, Li Q, Mohler ER 3rd, Schoen FJ, et al. (2001) Matrix metalloproteinase-2 is associated with tenascin-C in calcific aortic stenosis. Am J Pathol 159: 321-327.
9. Jian B, Narula N, Li QY, Mohler ER 3rd, Levy RJ, (2003) Progression of aortic valve stenosis: TGF-beta1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis. Ann Thorac Surg 75: 457-465; discussion 465-456.
10. O'Brien KD, Reichenbach DD, Marcovina SM, Kuusisto J, Alpers CE, et al. (1996) Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis. Arterioscler Thromb Vasc Biol 16: 523-532.
11. Rajamannan NM, Subramaniam M, Rickard D, Stock SR, Donovan J, et al. (2003) Human aortic valve calcification is associated with an osteoblast phenotype. Circulation 107: 2181-2184.
12. Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O'Brien KD, (1994) Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 90: 844-853.
13. Yetkin E, Waltenberger J, (2009) Molecular and cellular mechanisms of aortic stenosis. International Journal of Cardiology 135: 4-13.
14. Sacks MS, Yoganathan AP, (2007) Heart valve function: a biomechanical perspective. Philosophical Transactions of the Royal Society B: Biological Sciences 362: 1369-1391.
15. Butcher JT, Tressel S, Johnson T, Turner D, Sorescu G, et al. (2005) Transcriptional Profiles of Valvular and Vascular Endothelial Cells Reveal Phenotypic Differences. Influence of Shear Stress. Arterioscler Thromb Vasc Biol.
16. Ku DN, Giddens DP, Zarins CK, Glagov S, (1985) Pulsatile flow and atherosclerosis in the human carotid bifurcation. Positive correlation between plaque location and low oscillating shear stress. Arteriosclerosis 5: 293-302.
17. Weiss RM, Ohashi M, Miller JD, Young SG, Heistad DD, (2006) Calcific aortic valve stenosis in old hypercholesterolemic mice. Circulation 114: 2065-2069.
18. Zarins CK, Giddens DP, Bharadvaj BK, Sottiurai VS, Mabon RF, et al. (1983) Carotid bifurcation atherosclerosis. Quantitative correlation of plaque localization with flow velocity profiles and wall shear stress. Circ Res 53: 502-514.
19. Guerraty MA, Grant GR, Karanian JW, Chiesa OA, Pritchard WF, et al. (2010) Hypercholesterolemia Induces Side-Specific Phenotypic Changes and Peroxisome Proliferator-Activated Receptor-{gamma} Pathway Activation in Swine Aortic Valve Endothelium. Arterioscler Thromb Vasc Biol 30: 225-231.
20. Simmons CA, Grant GR, Manduchi E, Davies PF, (2005) Spatial heterogeneity of endothelial phenotypes correlates with side-specific vulnerability to calcification in normal porcine aortic valves. Circ Res 96: 792-799.
21. Mohler ER 3rd, Gannon F, Reynolds C, Zimmerman R, Keane MG, et al. (2001) Bone formation and inflammation in cardiac valves. Circulation 103: 1522-1528.
22. Hogan BL, (1996) Bone morphogenetic proteins in development. Curr Opin Genet Dev 6: 432-438.
23. Massague J, (2000) How cells read TGF-beta signals. Nat Rev Mol Cell Biol 1: 169-178.
24. Sorescu GP, Song H, Tressel SL, Hwang J, Dikalov S, et al. (2004) Bone morphogenic protein 4 produced in endothelial cells by oscillatory shear stress induces monocyte adhesion by stimulating reactive oxygen species production from a nox1-based NADPH oxidase. Circ Res 95: 773-779.
25. Sorescu GP, Sykes M, Weiss D, Platt MO, Saha A, et al. (2003) Bone morphogenic protein 4 produced in endothelial cells by oscillatory shear stress stimulates an inflammatory response. J Biol Chem 278: 31128-31135.
26. Miriyala S, Gongora Nieto MC, Mingone C, Smith D, Dikalov S, et al. (2006) Bone morphogenic protein-4 induces hypertension in mice: role of noggin, vascular NADPH oxidases, and impaired vasorelaxation. Circulation 113: 2818-2825.
27. Bostrom K, Watson KE, Horn S, Wortham C, Herman IM, et al. (1993) Bone morphogenetic protein expression in human atherosclerotic lesions. The Journal of Clinical Investigation 91: 1800-1809.
28. Piccolo S, Sasai Y, Lu B, De Robertis EM, (1996) Dorsoventral Patterning in Xenopus: Inhibition of Ventral Signals by Direct Binding of Chordin to BMP-4. Cell 86: 589-598.
29. Smith WC, Harland RM, (1992) Expression cloning of noggin, a new dorsalizing factor localized to the Spemann organizer in Xenopus embryos. Cell 70: 829-840.
30. Zimmerman LB, De Jesús-Escobar JM, Harland RM, (1996) The Spemann Organizer Signal noggin Binds and Inactivates Bone Morphogenetic Protein 4. Cell 86: 599-606.
31. Sudo S, Avsian-Kretchmer O, Wang LS, Hsueh AJW, (2004) Protein Related to DAN and Cerberus Is a Bone Morphogenetic Protein Antagonist That Participates in Ovarian Paracrine Regulation. Journal of Biological Chemistry 279: 23134-23141.
32. Hemmati-Brivanlou A, Kelly OG, Melton DA, (1994) Follistatin, an antagonist of activin, is expressed in the Spemann organizer and displays direct neuralizing activity. Cell 77: 283-295.
33. Nakamura T, Takio K, Eto Y, Shibai H, Titani K, et al. (1990) Activin-binding protein from rat ovary is follistatin. Science 247: 836-838.
34. Chang K, Weiss D, Suo J, Vega JD, Giddens D, et al. (2007) Bone Morphogenic Protein Antagonists Are Coexpressed With Bone Morphogenic Protein 4 in Endothelial Cells Exposed to Unstable Flow In Vitro in Mouse Aortas and in Human Coronary Arteries: Role of Bone Morphogenic Protein Antagonists in Inflammation and Atherosclerosis. Circulation 116: 1258-1266.
35. Koos R, Krueger T, Westenfeld R, Kuhl HP, Brandenburg V, et al. (2009) Relation of circulating matrix Gla-protein and anticoagulation status in patients with aortic valve calcificatiohn. Thrombbosis and Haemostasis 101: 605-794.
36. Massague J, Wotton D, (2000) Transcriptional control by the TGF-[beta]/Smad signaling system. EMBO J 19: 1745-1754.
37. Andrew LC, Carrie F, Chuanju L, Michael PL, Eric C, et al. (2004) Expression of bone morphogenetic proteins, receptors, and tissue inhibitors in human fetal, adult, and osteoarthritic articular cartilage. Journal of Orthopaedic Research 22: 1188-1192.
38. Sucosky P, Balachandran K, Elhammali A, Jo H, Yoganathan AP, (2009) Altered Shear Stress Stimulates Upregulation of Endothelial VCAM-1 and ICAM-1 in a BMP-4- and TGF-{beta}1-Dependent Pathway. Arterioscler Thromb Vasc Biol 29: 254-260.
39. Miyazono K, (1999) Signal transduction by bone morphogenetic protein receptors: functional roles of Smad proteins. Bone 25: 91-93.
40. Topper JN, Cai J, Qiu Y, Anderson KR, Xu Y-Y, et al. (1997) Vascular MADs: Two novel MAD-related genes selectively inducible by flow in human vascular endothelium. Proceedings of the National Academy of Sciences of the United States of America 94: 9314-9319.
41. Galvin KM, Donovan MJ, Lynch CA, Meyer RI, Paul RJ, et al. (2000) A role for Smad6 in development and homeostasis of the cardiovascular system. Nat Genet 24: 171-174.